Svetlana E. Serdyuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Svetlana E. Serdyuk has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Karapet V. Davtyan
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
8 shared publications - A. G. Topchyan
National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
4 shared publications - A. A. Brutyan
National Medical Research Center for Therapy and Preventive Medicine
3 shared publications - Aishat A. Abdullaeva
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
3 shared publications - Dmitriy Sergeevich Lebedev
Almazov National Medical Research Center
3 shared publications - Ekaterina V. Bazaeva
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
3 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 33 (3) , 67-76
«Trefoil» technique in cryoballoon isolation of the left common pulmonary vein trunk: clinical efficacy and anatomical predictors
Aim. To assess the relationship between left atrial (LA) and left common pulmonary vein (LCPV) anatomy and the clinical effectiveness of segmental cryoballoon isolation using the trefoil technique, and to identify independent predictors of procedural success in patients with atrial fibrillation (AF). Material and methods. This retrospective-prospective observational study included 98 patients with non-valvular AF and an LCPV diameter >28 mm and length >14 mm. All patients underwent segmental cryoballoon isolation using the trefoil technique. Clinically documented AF recurrence was assessed at 12 months. Patients with recurrence underwent repeat electrophysiological study with high-density electroanatomical mapping to evaluate the integrity of LCPV isolation. An effective outcome was defined as the absence of clinically documented AF recurrence or the presence of recurrence with confirmed preserved electrical isolation of the LCPV. An ineffective outcome was defined as clinically documented recurrence accompanied by confirmed reconnection of the LCPV. Associations between LA and LCPV anatomical parameters and clinical outcome were assessed using univariate and multivariate logistic regression analyses. Results. The clinical effectiveness of the proposed technique, taking the findings of repeat electrophysiological study (EPS) into account, was 86.7% (85 of 98 patients). Independent predictors of effectiveness were LA volume index (OR=0.952; 95% CI 0.913-0.992; p=0.020), LCPV ostial perimeter (OR=0.579; 95% CI 0.371-0.902; p=0.016), and the distance from the interatrial septum to the LCPV ostium (OR=0.691; 95% CI 0.512-0.933; p=0.016). Higher values of these parameters were associated with a lower probability of an effective outcome. The model was statistically significant and demonstrated good explanatory performance (Nagelkerke R²=0.564). An additional analysis of 30 patients who underwent repeat electrophysiological study confirmed the association of LA remodeling and LCPV morphology with preserved electrical isolation. Conclusion. Segmental cryoballoon isolation of the LCPV using the “trefoil” technique in patients with an LCPV diameter >28 mm and length >14 mm demonstrated high clinical efficacy, reaching 86.7% at 12-month follow-up. Independent predictors of preserved electrical isolation were left atrial volume index, LCPV ostial perimeter, and the distance from the interatrial septum to the LCPV ostium.
- 23 September 2026
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 33 (3) , 67-76
Open Access«Trefoil» technique in cryoballoon isolation of the left common pulmonary vein trunk: clinical efficacy and anatomical predictors
Aim. To assess the relationship between left atrial (LA) and left common pulmonary vein (LCPV) anatomy and the clinical effectiveness of segmental cryoballoon isolation using the trefoil technique, and to identify independent predictors of procedural success in patients with atrial fibrillation (AF). Material and methods. This retrospective-prospective observational study included 98 patients with non-valvular AF and an LCPV diameter >28 mm and length >14 mm. All patients underwent segmental cryoballoon isolation using the trefoil technique. Clinically documented AF recurrence was assessed at 12 months. Patients with recurrence underwent repeat electrophysiological study with high-density electroanatomical mapping to evaluate the integrity of LCPV isolation. An effective outcome was defined as the absence of clinically documented AF recurrence or the presence of recurrence with confirmed preserved electrical isolation of the LCPV. An ineffective outcome was defined as clinically documented recurrence accompanied by confirmed reconnection of the LCPV. Associations between LA and LCPV anatomical parameters and clinical outcome were assessed using univariate and multivariate logistic regression analyses. Results. The clinical effectiveness of the proposed technique, taking the findings of repeat electrophysiological study (EPS) into account, was 86.7% (85 of 98 patients). Independent predictors of effectiveness were LA volume index (OR=0.952; 95% CI 0.913-0.992; p=0.020), LCPV ostial perimeter (OR=0.579; 95% CI 0.371-0.902; p=0.016), and the distance from the interatrial septum to the LCPV ostium (OR=0.691; 95% CI 0.512-0.933; p=0.016). Higher values of these parameters were associated with a lower probability of an effective outcome. The model was statistically significant and demonstrated good explanatory performance (Nagelkerke R²=0.564). An additional analysis of 30 patients who underwent repeat electrophysiological study confirmed the association of LA remodeling and LCPV morphology with preserved electrical isolation. Conclusion. Segmental cryoballoon isolation of the LCPV using the “trefoil” technique in patients with an LCPV diameter >28 mm and length >14 mm demonstrated high clinical efficacy, reaching 86.7% at 12-month follow-up. Independent predictors of preserved electrical isolation were left atrial volume index, LCPV ostial perimeter, and the distance from the interatrial septum to the LCPV ostium.
- Open Access
- 31 July 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (6) , 4900
Profile of arrhythmias and conduction disorders in patients with familial hypertrophic cardiomyopathy: data from a multicenter registry
Aim . To analyze the profile of cardiac arrhythmias and conduction disorders in patients with familial hypertrophic cardiomyopathy (HCM) based on data from the registry of the National Medical Research Center for Therapy and Preventive Medicine and the Lomonosov Moscow State University (2021-2026). Material and methods . The analysis included 136 patients (48 men, 88 women; aged 19-78 years) — probands and relatives with a verified diagnosis or pathogenic variants in genes associated with HCM. All patients underwent additional examination, including electrocardiography (ECG) and Holter ECG monitoring. Based on this examination, 81 patients with arrhythmias and conduction disorders were identified. Genetic testing identified variants in the MYH7 , MYBPC3 , MYL2 , DSG2 , JPH2 , FLNC , ALPK3 , CACNA1C , ACTC1 , LDB3 , and TNNI3 genes in 60 patients. Results . Atrial fibrillation was recorded in 13,9% of cases (permanent in 3,7%, paroxysmal in 9,6%), ventricular premature beats in 59,6%, and ventricular fibrillation in 2,2%. Ventricular tachycardia (VT) was detected in 24,3% of all registry patients and in 34% of patients with gene variants (n=60). Degree I atrioventricular (AV) block was detected in 11% of cases, and degree II-III AV block — in 4,4%, left bundle branch block — in 5,9%. In genetic analysis, VT (80 vs 20%, p=0,001) and first degree AV block (45 vs 8%, padj=0,027) were more common in carriers of variants in the MYBPC3 gene (n=20) compared with MYH7 (n=25). The groups did not differ in interventricular septal thickness and left ventricular mass index after adjustment for sex, age and body mass index (BMI), whereas LV posterior wall thickness was higher in the MYBPC3 group (padj=0,028). The median risk of sudden cardiac death, calculated according to the Hypertrophic Cardiomyopathy. Risk-Sudden Cardiac Death (HCM Risk-SCD) score was 4,9% [3,4; 7,2] over 5 years n carriers in the MYBPC3 gene variants, compared to 3,1% [2,2; 6,8] (p=0,916) in carriers of MYH7 variants. However, no significant differences were found between the groups. Conclusion . The incidence of VT in familial HCM varies significantly depending on the genotype, reaching 80% in carriers of MYBPC3 variants. Patients with familial HCM, especially those carrying MYBPC3 variants, are recommended to undergo follow-up monitoring with Holter ECG every 6-12 months for the early detection of VT. Detection of VT allows for stratification of sudden cardiac death risk according to the HCM Risk-SCD score and determines indications for implantable cardioverter-defibrillator (ICD).
- 31 July 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (6) , 4900
Open AccessProfile of arrhythmias and conduction disorders in patients with familial hypertrophic cardiomyopathy: data from a multicenter registry
Aim . To analyze the profile of cardiac arrhythmias and conduction disorders in patients with familial hypertrophic cardiomyopathy (HCM) based on data from the registry of the National Medical Research Center for Therapy and Preventive Medicine and the Lomonosov Moscow State University (2021-2026). Material and methods . The analysis included 136 patients (48 men, 88 women; aged 19-78 years) — probands and relatives with a verified diagnosis or pathogenic variants in genes associated with HCM. All patients underwent additional examination, including electrocardiography (ECG) and Holter ECG monitoring. Based on this examination, 81 patients with arrhythmias and conduction disorders were identified. Genetic testing identified variants in the MYH7 , MYBPC3 , MYL2 , DSG2 , JPH2 , FLNC , ALPK3 , CACNA1C , ACTC1 , LDB3 , and TNNI3 genes in 60 patients. Results . Atrial fibrillation was recorded in 13,9% of cases (permanent in 3,7%, paroxysmal in 9,6%), ventricular premature beats in 59,6%, and ventricular fibrillation in 2,2%. Ventricular tachycardia (VT) was detected in 24,3% of all registry patients and in 34% of patients with gene variants (n=60). Degree I atrioventricular (AV) block was detected in 11% of cases, and degree II-III AV block — in 4,4%, left bundle branch block — in 5,9%. In genetic analysis, VT (80 vs 20%, p=0,001) and first degree AV block (45 vs 8%, padj=0,027) were more common in carriers of variants in the MYBPC3 gene (n=20) compared with MYH7 (n=25). The groups did not differ in interventricular septal thickness and left ventricular mass index after adjustment for sex, age and body mass index (BMI), whereas LV posterior wall thickness was higher in the MYBPC3 group (padj=0,028). The median risk of sudden cardiac death, calculated according to the Hypertrophic Cardiomyopathy. Risk-Sudden Cardiac Death (HCM Risk-SCD) score was 4,9% [3,4; 7,2] over 5 years n carriers in the MYBPC3 gene variants, compared to 3,1% [2,2; 6,8] (p=0,916) in carriers of MYH7 variants. However, no significant differences were found between the groups. Conclusion . The incidence of VT in familial HCM varies significantly depending on the genotype, reaching 80% in carriers of MYBPC3 variants. Patients with familial HCM, especially those carrying MYBPC3 variants, are recommended to undergo follow-up monitoring with Holter ECG every 6-12 months for the early detection of VT. Detection of VT allows for stratification of sudden cardiac death risk according to the HCM Risk-SCD score and determines indications for implantable cardioverter-defibrillator (ICD).
- Open Access
- 13 June 2026
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 33 (2) , 14-21
Correlation between pulmonary vein isolation efficacy and myocardial morphological changes
Aim . To investigate the correlation between the efficacy of pulmonary vein ostial isolation and morphological changes in the myocardium. Methods . The study included 118 patients with paroxysmal or persistent atrial fibrillation (AF) and no significant structural heart disease. All patients underwent primary cryoballoon isolation of the pulmonary vein ostia with simultaneous implantation of a loop ECG recorder (Medtronic Reveal XT) and myocardial biopsy of the interatrial septum (IAS) and the interventricular septum (IVS). Tissue samples were obtained before cryoballoon ablation (CBA). Patients were followed for one year with regular visits at 3, 6, and 12 months. If AF recurred, patients underwent a repeat electrophysiological study to assess the durability of pulmonary vein isolation. In cases of recovered pulmonary vein conduction, reisolation was performed, followed by another year of followup using the same visit schedule. Consequently, two patient groups were formed: those without AF recurrence (after one or two procedures) and those with recurrence (after two catheter isolation attempts). Results . Owing to an insufficient number of representative IAS biopsy samples (the biopsy material mainly consisted of the fibrous portion of the IAS), the analysis of the relationship between IAS morphological changes and nonpulmonaryveindependent AF recurrence could not be performed. In IVS biopsy samples, the most common morphological findings were myocardial hypertrophy, loss of myocardial crossstriation, endocardial thickening and lipomatosis, and cardiomyocyte dystrophy. Conclusion . In all AF patients without severe organic heart disease, various morphological changes of the IVS myocardium were identified, including fibrosis, lipomatosis, and dystrophy. Histological changes in myocardial biopsies from AF patients, such as cardiomyocyte degeneration and endocardial thickening, are important components of atrial remodelling that contribute to arrhythmia initiation, maintenance, and progression - consistent with the concept of atrial cardiomyopathy (atrial myopathy) regardless of its origin. A deeper understanding of these cellular and molecular changes may inform the development of novel targeted strategies for AF prevention and treatment. No clear predictors of a specific electrophysiological type of AF recurrence (pulmonaryveindependent vs. nonpulmonaryveindependent) after radiofrequency ablation were identified, which may reflect common underlying mechanisms and warrants further investigation.
- 13 June 2026
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 33 (2) , 14-21
Open AccessCorrelation between pulmonary vein isolation efficacy and myocardial morphological changes
Aim . To investigate the correlation between the efficacy of pulmonary vein ostial isolation and morphological changes in the myocardium. Methods . The study included 118 patients with paroxysmal or persistent atrial fibrillation (AF) and no significant structural heart disease. All patients underwent primary cryoballoon isolation of the pulmonary vein ostia with simultaneous implantation of a loop ECG recorder (Medtronic Reveal XT) and myocardial biopsy of the interatrial septum (IAS) and the interventricular septum (IVS). Tissue samples were obtained before cryoballoon ablation (CBA). Patients were followed for one year with regular visits at 3, 6, and 12 months. If AF recurred, patients underwent a repeat electrophysiological study to assess the durability of pulmonary vein isolation. In cases of recovered pulmonary vein conduction, reisolation was performed, followed by another year of followup using the same visit schedule. Consequently, two patient groups were formed: those without AF recurrence (after one or two procedures) and those with recurrence (after two catheter isolation attempts). Results . Owing to an insufficient number of representative IAS biopsy samples (the biopsy material mainly consisted of the fibrous portion of the IAS), the analysis of the relationship between IAS morphological changes and nonpulmonaryveindependent AF recurrence could not be performed. In IVS biopsy samples, the most common morphological findings were myocardial hypertrophy, loss of myocardial crossstriation, endocardial thickening and lipomatosis, and cardiomyocyte dystrophy. Conclusion . In all AF patients without severe organic heart disease, various morphological changes of the IVS myocardium were identified, including fibrosis, lipomatosis, and dystrophy. Histological changes in myocardial biopsies from AF patients, such as cardiomyocyte degeneration and endocardial thickening, are important components of atrial remodelling that contribute to arrhythmia initiation, maintenance, and progression - consistent with the concept of atrial cardiomyopathy (atrial myopathy) regardless of its origin. A deeper understanding of these cellular and molecular changes may inform the development of novel targeted strategies for AF prevention and treatment. No clear predictors of a specific electrophysiological type of AF recurrence (pulmonaryveindependent vs. nonpulmonaryveindependent) after radiofrequency ablation were identified, which may reflect common underlying mechanisms and warrants further investigation.
- Open Access
- 13 June 2026
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 33 (2) , 22-31
Combined antiarrhythmic therapy for refractory paroxysmal atrial fibrillation: a multicenter observational study
Aim . To evaluate the efficacy of the class IC antiarrhythmic drug flecainide in combination with an atrioventricular nodal slowing agent (metoprolol succinate or diltiazem) for the suppression of refractory to other antiarrhythmic medication atrial fibrillation (AF) in patients with symptomatic paroxysmal AF without significant structural heart disease, as well as to assess the incidence of adverse events associated with this therapy. Material and Methods . This multicenter observational study enrolled patients aged 18-75 years with documented symptomatic (EHRA class ≥2a) paroxysmal AF and frequent episodes (≥2 per month). All patients received flecainide combined with either metoprolol succinate or diltiazem. The primary endpoint was a documented episode of AF within 3 months of therapy. Secondary endpoints included time to AF recurrence and treatment-related adverse events. Rhythm monitoring was performed using a portable device for self-recording of lead I electrocardiograms: daily during the first week, twice weekly during weeks 2-4, and additionally on an ad hoc basis when symptoms occurred. Quality of life was assessed using the EQ-5D questionnaire at baseline and at study completion. Results . The study included 59 patients (57.6% female; mean age 63.5±9.9 years). The combination of flecainide with metoprolol succinate was prescribed to 93.2% (n=55) of patients, and flecainide with diltiazem to 6.8% (n=4). The primary endpoint was reached in 33.9% of patients (n=20). The majority of AF recurrences (85% of all events, n=17) occurred during the first month of follow-up. Adverse events were reported in 10.2% of cases (n=7). Conclusion . In patients with paroxysmal AF refractory to other antiarrhythmic drugs (including prior ineffective catheter ablation in half of the study patients), a combination of flecainide with metoprolol or diltiazem demonstrated a recurrence-free rate of 66% over 3 months, with an acceptable safety profile. Combination therapy is associated with a significant improvement in quality of life. Single-lead remote ECG monitoring is useful for detecting arrhythmia recurrences but is insufficient for a comprehensive assessment of the safety of intraventricular conduction disturbances.
- 13 June 2026
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 33 (2) , 22-31
Open AccessCombined antiarrhythmic therapy for refractory paroxysmal atrial fibrillation: a multicenter observational study
Aim . To evaluate the efficacy of the class IC antiarrhythmic drug flecainide in combination with an atrioventricular nodal slowing agent (metoprolol succinate or diltiazem) for the suppression of refractory to other antiarrhythmic medication atrial fibrillation (AF) in patients with symptomatic paroxysmal AF without significant structural heart disease, as well as to assess the incidence of adverse events associated with this therapy. Material and Methods . This multicenter observational study enrolled patients aged 18-75 years with documented symptomatic (EHRA class ≥2a) paroxysmal AF and frequent episodes (≥2 per month). All patients received flecainide combined with either metoprolol succinate or diltiazem. The primary endpoint was a documented episode of AF within 3 months of therapy. Secondary endpoints included time to AF recurrence and treatment-related adverse events. Rhythm monitoring was performed using a portable device for self-recording of lead I electrocardiograms: daily during the first week, twice weekly during weeks 2-4, and additionally on an ad hoc basis when symptoms occurred. Quality of life was assessed using the EQ-5D questionnaire at baseline and at study completion. Results . The study included 59 patients (57.6% female; mean age 63.5±9.9 years). The combination of flecainide with metoprolol succinate was prescribed to 93.2% (n=55) of patients, and flecainide with diltiazem to 6.8% (n=4). The primary endpoint was reached in 33.9% of patients (n=20). The majority of AF recurrences (85% of all events, n=17) occurred during the first month of follow-up. Adverse events were reported in 10.2% of cases (n=7). Conclusion . In patients with paroxysmal AF refractory to other antiarrhythmic drugs (including prior ineffective catheter ablation in half of the study patients), a combination of flecainide with metoprolol or diltiazem demonstrated a recurrence-free rate of 66% over 3 months, with an acceptable safety profile. Combination therapy is associated with a significant improvement in quality of life. Single-lead remote ECG monitoring is useful for detecting arrhythmia recurrences but is insufficient for a comprehensive assessment of the safety of intraventricular conduction disturbances.
- Open Access
- 4 June 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (4) , 6949
Selection of class IC antiarrhythmic agent for the treatment of cardiac arrhythmias: from pharmacological properties to patient profile. Expert Council resolution
Class IC antiarrhythmic drugs continue to play a pivotal role in the management of a wide range of cardiac arrhythmias, despite the rapid development of interventional arrhythmology and the expanding indications for catheterbased therapies. Although these agents share common mechanisms of action, their differences in pharmacodynamics, pharmacokinetics, and effects on the cardiac conduction system require a differentiated approach to drug selection across various clinical settings. The Expert Council aimed to analyze the pharmacological characteristics, efficacy, and safety of the Class IC antiarrhythmic agent ethacizine. Practical guidelines were developed for selecting Class IC antiarrhythmic therapy with consideration of arrhythmogenic mechanisms, comorbid conditions, and the patient’s vital and electrophysiological characteristics. In addition, clinical scenarios were identified in which ethacizine may be regarded as the drug of choice.
- 4 June 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (4) , 6949
Open AccessSelection of class IC antiarrhythmic agent for the treatment of cardiac arrhythmias: from pharmacological properties to patient profile. Expert Council resolution
Class IC antiarrhythmic drugs continue to play a pivotal role in the management of a wide range of cardiac arrhythmias, despite the rapid development of interventional arrhythmology and the expanding indications for catheterbased therapies. Although these agents share common mechanisms of action, their differences in pharmacodynamics, pharmacokinetics, and effects on the cardiac conduction system require a differentiated approach to drug selection across various clinical settings. The Expert Council aimed to analyze the pharmacological characteristics, efficacy, and safety of the Class IC antiarrhythmic agent ethacizine. Practical guidelines were developed for selecting Class IC antiarrhythmic therapy with consideration of arrhythmogenic mechanisms, comorbid conditions, and the patient’s vital and electrophysiological characteristics. In addition, clinical scenarios were identified in which ethacizine may be regarded as the drug of choice.
- Open Access
- 9 January 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (1) , 39
Atrial Fibrillation Recurrence After Catheter Ablation Is Associated with TAG72 Protein
Despite the efficacy of catheter ablation in preventing recurrences of atrial fibrillation (AF), the reasons for its lack of success in some patients remain unknown. The aim of this study was to try to identify a new predictor of AF recurrence following catheter-based treatment. This prospective study enrolled a cohort of patients with AF. Based on the results of a one-year follow-up, patients were divided into two groups: Group 1 (“vein-dependent” AF)—patients who achieved a successful outcome after 1–2 catheter ablation procedures—and Group 2 (“non-vein-dependent” AF)—patients with confirmed complete pulmonary vein isolation (PVI) or with an identified “non-vein-dependent” AF substrate. Blood samples were collected prior to the procedure and biobanked. Initial proteomic profiling of the serum using protein microarrays identified several candidate proteins, whose elevated levels were subsequently confirmed by an enzyme-linked immunosorbent assay (ELISA). This article presents data on one such protein—TAG72. A comparison of TAG72 levels (%OD normalized units) between Group 1 (“vein-dependent” AF) and Group 2 (“non-vein-dependent” AF) revealed a statistically significant increase in the latter group (128.9 [98.2; 284.4] vs. 84.3 [73.8; 92.1], p < 0.001). These data provide the first evidence implicating TAG72 in the pathogenesis of AF.
- 9 January 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (1) , 39
Open AccessAtrial Fibrillation Recurrence After Catheter Ablation Is Associated with TAG72 Protein
Despite the efficacy of catheter ablation in preventing recurrences of atrial fibrillation (AF), the reasons for its lack of success in some patients remain unknown. The aim of this study was to try to identify a new predictor of AF recurrence following catheter-based treatment. This prospective study enrolled a cohort of patients with AF. Based on the results of a one-year follow-up, patients were divided into two groups: Group 1 (“vein-dependent” AF)—patients who achieved a successful outcome after 1–2 catheter ablation procedures—and Group 2 (“non-vein-dependent” AF)—patients with confirmed complete pulmonary vein isolation (PVI) or with an identified “non-vein-dependent” AF substrate. Blood samples were collected prior to the procedure and biobanked. Initial proteomic profiling of the serum using protein microarrays identified several candidate proteins, whose elevated levels were subsequently confirmed by an enzyme-linked immunosorbent assay (ELISA). This article presents data on one such protein—TAG72. A comparison of TAG72 levels (%OD normalized units) between Group 1 (“vein-dependent” AF) and Group 2 (“non-vein-dependent” AF) revealed a statistically significant increase in the latter group (128.9 [98.2; 284.4] vs. 84.3 [73.8; 92.1], p < 0.001). These data provide the first evidence implicating TAG72 in the pathogenesis of AF.
- Open Access
- 26 September 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-6
Does cryoballoon ablation affect the symptom severity of atrial fibrillation? Insights from 12-months continuous cardiac monitoring
Most data on asymptomatic atrial fibrillation (AF) recurrence following catheter ablation primarily derive from studies on radiofrequency ablation (RFA). Our previous study with a small sample size revealed no significant difference in AF freedom rates detected via patient history, ECG, Holter monitoring, and continuous cardiac monitoring in the cryoballoon ablation (CBA) group. This study aims to evaluate alterations in AF symptoms following pulmonary vein (PV) CBA using implantable loop recorders (ILR) and patient-reported data. A total of 145 patients with highly symptomatic AF (EHRA score ≥ 2b) were consecutively enrolled and underwent primary PV CBA with simultaneous ILR implantation. Follow-up visits occurred at 3-, 6-, and 12-months post-ablation. Data were collected from patients’ symptom logs, ILR readings, and clinical events at each visit. Clinical efficacy was defined as the absence of AF recurrence based on patients’ symptom logs, while absolute efficacy was defined as the absence of AF detected by ILR. ILR detection served as the reference standard, and detection via patient symptom log was considered the test method. The absolute efficacy was 57,2% (n = 83). All cases of AF relapse were also reported by patients in their symptom logs. Agreement between patient-reported data and ILR data was substantial, with a κ statistic value of 0.98. The agreement between patient-reported data and ILR data showed a κ statistic value of 0.98. CBA using second-generation cryoballoon does not significantly alter AF symptom perception in highly symptomatic patients. Cardiac rhythm in these patients might be effectively monitored through symptom logs, ECGs, or Holter monitoring. ClinicalTrials.gov NCT03587181, SubstrateAF study, first posted date July 16, 2018.
- 26 September 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-6
Open AccessDoes cryoballoon ablation affect the symptom severity of atrial fibrillation? Insights from 12-months continuous cardiac monitoring
Most data on asymptomatic atrial fibrillation (AF) recurrence following catheter ablation primarily derive from studies on radiofrequency ablation (RFA). Our previous study with a small sample size revealed no significant difference in AF freedom rates detected via patient history, ECG, Holter monitoring, and continuous cardiac monitoring in the cryoballoon ablation (CBA) group. This study aims to evaluate alterations in AF symptoms following pulmonary vein (PV) CBA using implantable loop recorders (ILR) and patient-reported data. A total of 145 patients with highly symptomatic AF (EHRA score ≥ 2b) were consecutively enrolled and underwent primary PV CBA with simultaneous ILR implantation. Follow-up visits occurred at 3-, 6-, and 12-months post-ablation. Data were collected from patients’ symptom logs, ILR readings, and clinical events at each visit. Clinical efficacy was defined as the absence of AF recurrence based on patients’ symptom logs, while absolute efficacy was defined as the absence of AF detected by ILR. ILR detection served as the reference standard, and detection via patient symptom log was considered the test method. The absolute efficacy was 57,2% (n = 83). All cases of AF relapse were also reported by patients in their symptom logs. Agreement between patient-reported data and ILR data was substantial, with a κ statistic value of 0.98. The agreement between patient-reported data and ILR data showed a κ statistic value of 0.98. CBA using second-generation cryoballoon does not significantly alter AF symptom perception in highly symptomatic patients. Cardiac rhythm in these patients might be effectively monitored through symptom logs, ECGs, or Holter monitoring. ClinicalTrials.gov NCT03587181, SubstrateAF study, first posted date July 16, 2018.
- Open Access
- 7 February 2025
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 32 (1) , 5-16
Russian registry of cryoballon ablation of atrial fibrillation: characteristics of the procedure and features of patient’s management
Aim. To study the characteristics of the atrial fibrillation (AF) cryoballoon ablation (CBA) procedure and features of patient’s management in real clinical practice in Russia.Methods. “Prospective Atrial Fibrillation Cryoablation Registry” is an observational prospective national multicenter study. It was conducted from 01.2017 to 12.2019 in centers of Russian Federation. The registry included patients over the age of 18 who were agreed to participate this study and had indications for CBA of AF. The study protocol did not provide for significant restrictions on inclusion criteria, procedure technique and postoperative follow-up. The data was collected prior to the CBA of AF, during hospitalization for CBA and on the 12-month follow-up.Results. Participating centers enroll 980 patients according to inclusion criteria. CBA of AF was performed in 976 (99.6%) (mean age 59.7±9.2 years, 545 (55.8%) men) primary procedure - 840 (86.1%), re-ablation - 136 (13.9%). Parox- ysmal AF occurred in 828 (84.8%) patients and persistent AF (mean time of persistence 4.4±3.7 months) - in 145 (15.1%) patients. The average procedure time was 108.1±33.3 minutes and mean fluoroscopy time was 24.9±13.6 min. Most of the procedures were performed under general anesthesia. Complications after AF CBA occurred in 53 (5.4%) patients. The most common complication was paresis of the phrenic nerve - 20 (37.7%) cases which were associated with lower temperatures of CBA application of the right pulmonary veins (τ=0.08; pConclusion. CBA is an effective and relatively safe procedure for the treatment of paroxysmal and persistent AF. Data from real clinical practice show a low proportion of serious complications of AF CBA. Data on the dynamics of drug therapy, including anticoagulant and antiarrhythmic therapy, were obtained. The attention of specialists performing AF catheter ablation and patient monitoring is required, since errors in patient management have been identified.
- 7 February 2025
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 32 (1) , 5-16
Open AccessRussian registry of cryoballon ablation of atrial fibrillation: characteristics of the procedure and features of patient’s management
Aim. To study the characteristics of the atrial fibrillation (AF) cryoballoon ablation (CBA) procedure and features of patient’s management in real clinical practice in Russia.Methods. “Prospective Atrial Fibrillation Cryoablation Registry” is an observational prospective national multicenter study. It was conducted from 01.2017 to 12.2019 in centers of Russian Federation. The registry included patients over the age of 18 who were agreed to participate this study and had indications for CBA of AF. The study protocol did not provide for significant restrictions on inclusion criteria, procedure technique and postoperative follow-up. The data was collected prior to the CBA of AF, during hospitalization for CBA and on the 12-month follow-up.Results. Participating centers enroll 980 patients according to inclusion criteria. CBA of AF was performed in 976 (99.6%) (mean age 59.7±9.2 years, 545 (55.8%) men) primary procedure - 840 (86.1%), re-ablation - 136 (13.9%). Parox- ysmal AF occurred in 828 (84.8%) patients and persistent AF (mean time of persistence 4.4±3.7 months) - in 145 (15.1%) patients. The average procedure time was 108.1±33.3 minutes and mean fluoroscopy time was 24.9±13.6 min. Most of the procedures were performed under general anesthesia. Complications after AF CBA occurred in 53 (5.4%) patients. The most common complication was paresis of the phrenic nerve - 20 (37.7%) cases which were associated with lower temperatures of CBA application of the right pulmonary veins (τ=0.08; pConclusion. CBA is an effective and relatively safe procedure for the treatment of paroxysmal and persistent AF. Data from real clinical practice show a low proportion of serious complications of AF CBA. Data on the dynamics of drug therapy, including anticoagulant and antiarrhythmic therapy, were obtained. The attention of specialists performing AF catheter ablation and patient monitoring is required, since errors in patient management have been identified.
- Open Access
- 13 January 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-5
Continuous cardiac monitoring in epilepsy: an implantable loop manual activation algorithm for improving ECG signal acquisition accuracy
The muscle artifacts, caused by prominent muscle contractions, mimicking cardiac arrhythmias, might compromise the ECG signal quality and the implantable loop recorder memory capacity in patients with epilepsy. We developed an epileptic seizures clinical pattern-based implantable loop recorder manual activation algorithm, presenting its real-world efficacy here. One hundred ninety-three patients (18–60 years) with drug-resistant focal epilepsy were consecutively enrolled and underwent a subcutaneous loop recorder implantation. Patients with focal onset-aware seizures and patients with focal impaired awareness seizures /bilateral tonic-clonic seizures without aura were recommended to use the activator once - just after the episode. Patients with focal impaired awareness seizures/bilateral tonic-clonic seizures with aura, the caregivers of patients experiencing status epilepticus, were advised to use the activator twice - during the aura and after the episode/ regaining consciousness. Six thousand four hundred ninety-four ECG traces (4826 - auto-triggered events, 1668 - person-activated events) were recorded and analyzed. The rate of true positive events in the person-activated group was statistically higher than in the autoactivation group (72.5% vs.19.4%, p < 0.0001). Person-activated false-positive events were observed in 30.5% of patients with focal impaired awareness seizures and 27.7% in patients with bilateral tonic-clonic seizures. The highest rate of false-positive events (61.5%) was detected in patients undergoing epileptic status, and the lowest rate (3.8%) - was in patients with focal onset aware seizures. The rate of false-positive events was significantly higher in patients with impaired awareness seizures without aura both in focal impaired awareness (45.5% vs. 19.3%, p < 0.0001) and bilateral tonic-clonic seizure groups (38.8% vs. 5.9%, p < 0.0001). Arrhythmias with varying clinical outcomes are expected in epilepsy patients and have been monitored continuously. The specified loop recorder external activation algorithm can improve the clinically relevant cardiac arrhythmia detection accuracy in epilepsy patients and the value of future studies.
- 13 January 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-5
Open AccessContinuous cardiac monitoring in epilepsy: an implantable loop manual activation algorithm for improving ECG signal acquisition accuracy
The muscle artifacts, caused by prominent muscle contractions, mimicking cardiac arrhythmias, might compromise the ECG signal quality and the implantable loop recorder memory capacity in patients with epilepsy. We developed an epileptic seizures clinical pattern-based implantable loop recorder manual activation algorithm, presenting its real-world efficacy here. One hundred ninety-three patients (18–60 years) with drug-resistant focal epilepsy were consecutively enrolled and underwent a subcutaneous loop recorder implantation. Patients with focal onset-aware seizures and patients with focal impaired awareness seizures /bilateral tonic-clonic seizures without aura were recommended to use the activator once - just after the episode. Patients with focal impaired awareness seizures/bilateral tonic-clonic seizures with aura, the caregivers of patients experiencing status epilepticus, were advised to use the activator twice - during the aura and after the episode/ regaining consciousness. Six thousand four hundred ninety-four ECG traces (4826 - auto-triggered events, 1668 - person-activated events) were recorded and analyzed. The rate of true positive events in the person-activated group was statistically higher than in the autoactivation group (72.5% vs.19.4%, p < 0.0001). Person-activated false-positive events were observed in 30.5% of patients with focal impaired awareness seizures and 27.7% in patients with bilateral tonic-clonic seizures. The highest rate of false-positive events (61.5%) was detected in patients undergoing epileptic status, and the lowest rate (3.8%) - was in patients with focal onset aware seizures. The rate of false-positive events was significantly higher in patients with impaired awareness seizures without aura both in focal impaired awareness (45.5% vs. 19.3%, p < 0.0001) and bilateral tonic-clonic seizure groups (38.8% vs. 5.9%, p < 0.0001). Arrhythmias with varying clinical outcomes are expected in epilepsy patients and have been monitored continuously. The specified loop recorder external activation algorithm can improve the clinically relevant cardiac arrhythmia detection accuracy in epilepsy patients and the value of future studies.
- 1 February 2021
- Published by Elsevier in Heart Rhythm
- Vol. 18 (2) , 221-228
Cardiac arrhythmias and sudden unexpected death in epilepsy: Results of long-term monitoring
- 1 February 2021
- Published by Elsevier in Heart Rhythm
- Vol. 18 (2) , 221-228
Cardiac arrhythmias and sudden unexpected death in epilepsy: Results of long-term monitoring